Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 430 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vomiting Clear all
Completed Phase 1 Interventional

The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer

NCT00440128
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Docetaxel, Casopitant/Docetaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Hot Springs, Arkansas • Iowa City, Iowa • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2017 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older · Female only
Enrollment
1,363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Honolulu, Hawaii • Decatur, Illinois • New Orleans, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Results available

A Study of Kytril (Granisetron) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy

NCT00231478
View directory record Official record
Conditions
Post-Operative Nausea and Vomiting
Interventions
granisetron
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 16 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Fresno, California • Stanford, California • Hartford, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 20, 2026, 10:49 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Surgical Site Infiltration of Exparel vs TAP Block With Exparel in Patients Undergoing Laparotomy Via Midline Incision

NCT03870685
View directory record Official record
Conditions
Postoperative Pain, Postoperative Nausea and Vomiting, Opioid Use
Interventions
TAP Block, Surgical Site Infiltration, Exparel
Procedure · Drug
Lead sponsor
Danbury Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Danbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Prospective Controlled Trial On Clear Feeds Versus Low Residue Diet After Surgery In Elective Colorectal Surgery Patients

NCT01890499
View directory record Official record
Conditions
Nausea/Vomiting
Interventions
Low Residue diet arm.
Dietary Supplement
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Not applicable Interventional Results available

Aprepitant for Post-operative Nausea

NCT01020903
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Aprepitant, Placebo
Procedure · Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 20, 2026, 10:49 AM EDT
Suspended Phase 3 Interventional Accepts healthy volunteers

The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

NCT05289557
View directory record Official record
Conditions
Morning Sickness
Interventions
Bonjesta, Placebo
Drug
Lead sponsor
Duchesnay Inc.
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
10
States / cities
Burbank, California • Hialeah, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 10:49 AM EDT
Terminated Phase 3 Interventional Results available

Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate Tissue Expander (TE) Reconstruction

NCT02161705
View directory record Official record
Conditions
Postoperative Pain, Postoperative Nausea and Vomiting, Quality of Life
Interventions
Ropivacaine, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Pragmatic Research eXamining Inpatient Symptoms

NCT01988194
View directory record Official record
Conditions
Postoperative Pain, Nausea, Vomiting, Anxiety, Depression
Interventions
Acupuncture
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

NCT00795769
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma
Interventions
ondansetron, survey administration, management of therapy complications
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
21 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Not applicable Interventional

AroMatherapy for Blood and Marrow Transplant PatIENTs (AMBIENT)

NCT03621722
View directory record Official record
Conditions
Anxiety, Nausea, Vomiting
Interventions
Elequil Aromatabs
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 20, 2026, 10:49 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

NCT05452174
View directory record Official record
Conditions
Pregnancy, Severe Nausea and Vomiting, Hyperemesis Gravidarum
Interventions
Mirtazapine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 20, 2026, 10:49 AM EDT
Active, not recruiting Phase 2 Interventional

Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ

NCT03935685
View directory record Official record
Conditions
Glioma of Brain
Interventions
Mirtazapine (Remeron)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Acupuncture for Prevention of Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

NCT05975385
View directory record Official record
Conditions
Cholecystitis, Acute, Cholelithiasis, Nausea, Postoperative, Vomiting, Postoperative, Pain, Postoperative
Interventions
Acupuncture
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 2 Interventional

The Safety and Efficacy of Dexloxiglumide for the Relief of Symptoms of Functional Dyspepsia.

NCT00303264
View directory record Official record
Conditions
Dyspepsia
Interventions
dexloxiglumide, Nexium (esomeprazole)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

Sancuso® for Gastroparesis: An Open Label Study.

NCT01989221
View directory record Official record
Conditions
Gastroparesis
Interventions
Sancuso®
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 20, 2026, 10:49 AM EDT
Completed No phase listed Observational Results available

Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia

NCT02602080
View directory record Official record
Conditions
Nausea, Emesis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 10:49 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

NCT05244460
View directory record Official record
Conditions
Cannabis Hyperemesis Syndrome
Interventions
Droperidol Injectable Product, Diphenhydramine
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Austintown, Ohio • Boardman, Ohio • Warren, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section

NCT02960113
View directory record Official record
Conditions
Nausea, Vomiting, Satisfaction
Interventions
scopolamine patch, acupressure point P6
Drug · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Surgeon Perception of Gastric Decompression at Time of Gynecologic Laparoscopy

NCT06137976
View directory record Official record
Conditions
Gynecologic Surgical Procedures, Gastric Injury, Aspiration, Nausea, Postoperative, Postoperative Complications, Enhanced Recovery After Surgery, Laparoscopy
Interventions
Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections

NCT01734161
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 46 Years · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 20, 2026, 10:49 AM EDT
Terminated Phase 2 Interventional Results available

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00895245
View directory record Official record
Conditions
Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy
Drug · Other · Behavioral + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Transcutaneous Electroacupuncture for Gastroparesis

NCT01469286
View directory record Official record
Conditions
Diabetic Gastroparesis
Interventions
TEA, Sham-TEA
Device
Lead sponsor
Transtimulation Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Jackson, Mississippi • El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 20, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors

NCT00086762
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Gastrointestinal Cancer, Disease (or Disorder); Gynecological, Prostate Cancer
Interventions
MR Therapy, Relaxing Music (RM) Therapy, Standard Symptom Management, Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
9
States / cities
Wichita, Kansas • Ann Arbor, Michigan • Grand Rapids, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 20, 2026, 10:49 AM EDT